Literature DB >> 11035019

DNA recognition by the methyl-CpG binding domain of MeCP2.

A Free1, R I Wakefield, B O Smith, D T Dryden, P N Barlow, A P Bird.   

Abstract

The methyl-CpG binding domain (MBD) of the transcriptional repressor MeCP2 has been proposed to recognize a single symmetrically methylated CpG base pair via hydrophobic patches on an otherwise positively charged DNA binding surface. We have tested this binding model by analysis of mutant derivatives of the MeCP2 MBD in electrophoretic mobility shift assays complemented by NMR structural analysis. Exposed arginine side chains on the binding face, in particular Arg-111, were found to be critical for binding. Arg-111 was found to interact with the conserved aspartate side chain Asp-121, which is proposed to orientate the arginine side chain to allow specific contacts with the DNA. The conformational flexibility of the disordered B-C loop region, which forms part of the binding face, was also shown to be important. In contrast, mutation of the exposed hydrophobic side chains had a less severe effect on DNA binding. This suggests that the Arg-111 side chain may contribute to sequence-specific recognition of the CpG site rather than simply making nonspecific contacts with the phosphate backbone. The majority of missense mutations within the MBD found in the human genetic disorder Rett syndrome were shown or predicted to affect folding of the domain rather than the DNA recognition event directly.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035019     DOI: 10.1074/jbc.M007224200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor.

Authors:  A Prokhortchouk; B Hendrich; H Jørgensen; A Ruzov; M Wilm; G Georgiev; A Bird; E Prokhortchouk
Journal:  Genes Dev       Date:  2001-07-01       Impact factor: 11.361

2.  Structure of the sporulation-specific transcription factor Ndt80 bound to DNA.

Authors:  Jason S Lamoureux; David Stuart; Roger Tsang; Cynthia Wu; J N Mark Glover
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

Review 3.  Rett syndrome and MeCP2: linking epigenetics and neuronal function.

Authors:  Mona D Shahbazian; Huda Y Zoghbi
Journal:  Am J Hum Genet       Date:  2002-11-19       Impact factor: 11.025

Review 4.  Eukaryotic methyl-CpG-binding domain proteins and chromatin modification.

Authors:  Ming-Shiu Hung; C-K James Shen
Journal:  Eukaryot Cell       Date:  2003-10

Review 5.  Human non-CG methylation: are human stem cells plant-like?

Authors:  Olga V Dyachenko; Tara V Schevchuk; Leo Kretzner; Yaroslav I Buryanov; Steven S Smith
Journal:  Epigenetics       Date:  2010-10-01       Impact factor: 4.528

6.  Multiple modes of interaction between the methylated DNA binding protein MeCP2 and chromatin.

Authors:  Tatiana Nikitina; Xi Shi; Rajarshi P Ghosh; Rachel A Horowitz-Scherer; Jeffrey C Hansen; Christopher L Woodcock
Journal:  Mol Cell Biol       Date:  2006-11-13       Impact factor: 4.272

7.  Impact of base analogues within a CpG dinucleotide on the binding of DNA by the methyl-binding domain of MeCP2 and methylation by DNMT1.

Authors:  Victoria Valinluck Lao; Agus Darwanto; Lawrence C Sowers
Journal:  Biochemistry       Date:  2010-11-09       Impact factor: 3.162

8.  Towards understanding the epigenetics of transcription by chromatin structure and the nuclear matrix.

Authors:  Rui Pires Martins; Stephen A Krawetz
Journal:  Gene Ther Mol Biol       Date:  2005

9.  Heterogeneity in residual function of MeCP2 carrying missense mutations in the methyl CpG binding domain.

Authors:  S Kudo; Y Nomura; M Segawa; N Fujita; M Nakao; C Schanen; M Tamura
Journal:  J Med Genet       Date:  2003-07       Impact factor: 6.318

10.  Differential binding of Escherichia coli McrA protein to DNA sequences that contain the dinucleotide m5CpG.

Authors:  Elizabeth A Mulligan; Eli Hatchwell; Sean R McCorkle; John J Dunn
Journal:  Nucleic Acids Res       Date:  2009-12-16       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.